



8th October, 2009

Haemorol™ (oily phenol injection) has marketing approval in Australia and New Zealand

Phebra is pleased to announce that it has achieved marketing approval for Haemorol™ in Australia and New Zealand.

Haemorol™ is indicated for the treatment of first and second degree symptomatic haemorrhoids in patients who have had an inadequate response to dietary therapy.

“This has been a challenging project for Phebra and we are very pleased to gain approval by the TGA and Medsafe for marketing Haemorol™”, said Dr Mal Eutick, CEO of Phebra, “we understand that Haemorol™ Injection is an essential therapeutic option for clinicians who manage haemorrhoids and we are very pleased to have improved the supply of this medicine in Australia and New Zealand”.

Phebra will be marketing Haemorol™ Injection to Australian hospitals and wholesalers. Haemorol™ is available in New Zealand from AFT Pharmaceuticals.

Phebra is an Australian based specialty pharmaceutical company that develops and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe. For more information about Phebra please refer to the company website at www.phebra.com.

At Phebra, we create critical medicines that save and improve lives.